Study of HA121-28 in Patients With Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, single-arm phase II study to evaluate efficacy and
safety of HA121-28 tablets in patients with rearranged during transfection (RET)
fusion-positive advanced non-small cell lung cancer (NSCLC).